531294 Sigma-AldrichPerk Inhibitor III, LDN-0070977 - Calbiochem
A cell-permeable, reversible, and non ATP-competitive inhibitor of PERK (PKR-like ER kinase, IC₅₀ = 7.04 µM) and blocks PERK-dependent phosphorylation of elF2a.
More>> A cell-permeable, reversible, and non ATP-competitive inhibitor of PERK (PKR-like ER kinase, IC₅₀ = 7.04 µM) and blocks PERK-dependent phosphorylation of elF2a. Less<<Perk Inhibitor III, LDN-0070977 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Synonyms: PKR-like ER kinase Inhibitor, LDN-0070977, LDN0070977, LDN 0070977
Recommended Products
Overview
Replacement Information |
---|
Key Specifications Table
Empirical Formula |
---|
C₁₂H₈N₂O |
Pricing & Availability
Catalog Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
5.31294.0001 |
|
Glass bottle | 10 mg |
|
— |
References | |
---|---|
References | Pytel, D., et al. 2014. J. Biomol. Screen. 19, 1024. |
Product Information | |
---|---|
Form | Off-white powder |
Hill Formula | C₁₂H₈N₂O |
Chemical formula | C₁₂H₈N₂O |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | PERK |
Primary Target IC<sub>50</sub> | 7µ |
Purity | ≥98% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Documentation
Perk Inhibitor III, LDN-0070977 - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Pytel, D., et al. 2014. J. Biomol. Screen. 19, 1024. |
Technical Info
Title |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. (EMD) |